Daratumumab (Dara) is the first-in-class human-specific anti-CD38 mAb approved for the treatment of multiple myeloma (MM). Although recent data have demonstrated very promising results in clinical practice and trials. some patients do not achieve a partial response. and ultimately all patients undergo progression. https://www.spidertattooz.com/OPI-GelColor-The-Color-That-Keeps-On-Giving-0-5-oz-HPJ07-p22791/